Opiant Pharmaceuticals, Inc. (OPNT)

Opiant Pharmaceuticals, Inc. (OPNT) Healthcare & Pipeline Overview

Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing treatments for addictions and drug overdose. Headquartered in Santa Monica, California, it offers NARCAN nasal spray for opioid overdose reversal and maintains a pipeline targeting alcohol use disorders, acute cannabinoid overdose, and opioid use disorders.

What Is the Investment Thesis for OPNT?

Opiant Pharmaceuticals, Inc. presents an investment profile centered on its established commercial product, NARCAN nasal spray, and a pipeline addressing significant unmet medical needs in addiction and overdose. With a market capitalization of $108.80M and a P/E ratio of 30.6, the company demonstrates profitability, evidenced by a 7.4% profit margin and a robust 77.7% gross margin. The company's beta of 0.83 suggests lower volatility compared to the broader market. Key value drivers include the continued demand for opioid overdose reversal treatments and the potential for pipeline assets to achieve regulatory approval and commercialization. Growth catalysts are primarily tied to the successful progression of its drug candidates for alcohol use disorders, acute cannabinoid overdose, and opioid use disorders through clinical trials. However, the investment carries inherent risks associated with pharmaceutical development, including regulatory hurdles, clinical trial outcomes, and market competition within the specialized addiction treatment sector.

Based on FMP financials and quantitative analysis

OPNT Key Highlights

• Market capitalization stands at $0.11 billion, reflecting its position as a specialized biotechnology company.
• Achieved a P/E ratio of 30.6, indicating investor expectations for future earnings relative to its current share price.
• Maintains a profit margin of 7.4%, demonstrating its ability to convert revenue into net income.
• Boasts a strong gross margin of 77.7%, highlighting efficient cost management in its product development and sales.
• Exhibits a Beta of 0.83, suggesting lower price volatility compared to the overall market.

Who Are OPNT's Competitors?

OPNT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OPNT's Key Strengths?

• Established commercial product (NARCAN nasal spray) with significant market presence in opioid overdose reversal.
• Focused pipeline addressing critical and growing public health issues in addiction medicine.
• Strong gross margin (77.7%) indicates efficient operations and product profitability.
• Experienced leadership team with a clear strategic direction in specialty pharmaceuticals.

What Are OPNT's Weaknesses?

• Relatively small employee base (37 employees) compared to larger pharmaceutical companies, potentially limiting R&D scale.
• Reliance on a single primary commercial product (NARCAN) for current revenue generation.
• Pipeline products are in various stages of development, carrying inherent clinical trial risks.
• Limited geographic reach explicitly mentioned in the provided data.

What Could Drive OPNT Stock Higher?

• Progression of the alcohol use disorder (AUD) candidate through pivotal clinical trials, with potential for data readouts in late 2026 or early 2027.
• Advancement of the acute cannabinoid overdose (ACO) treatment candidate into later-stage clinical development, expected by mid-2027.
• Continued commercial performance and market penetration of NARCAN nasal spray, contributing to stable revenue streams.
• Potential initiation of new clinical studies for opioid use disorder (OUD) candidates, expanding the company's long-term growth prospects in 2027-2028.

What Are the Key Risks for OPNT?

• Rich valuation — a P/E of 30.6 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Insider selling — insiders were net sellers of roughly $1.9M recently.
• Clinical trial failures or unexpected adverse events for pipeline candidates could significantly delay or halt product development and regulatory approval.
• Intense competition in the addiction treatment market from larger pharmaceutical companies with greater financial and marketing resources.
• Regulatory delays or non-approvals from health authorities (e.g., FDA) for new drug candidates, impacting time-to-market and commercial viability.
• Dependence on the continued commercial success of NARCAN nasal spray, making the company susceptible to market shifts or competitive pressures in opioid overdose reversal.
• Changes in healthcare policy, reimbursement rates, or public funding for addiction treatments could negatively impact product adoption and revenue generation.

What Are the Growth Opportunities for OPNT?

• **Expansion into Alcohol Use Disorder (AUD) Treatment:** Opiant's pipeline includes a candidate for alcohol use disorders, representing a significant growth opportunity. AUD affects millions globally, with limited effective and accessible treatment options. Developing a new, efficacious treatment could tap into a market valued in the billions, driven by chronic nature of the condition and increasing awareness. Successful clinical trials and regulatory approval for this candidate could provide Opiant with a new revenue stream, diversifying its product portfolio beyond opioid-related treatments and addressing a distinct patient population, with potential market entry within the next 3-5 years, subject to regulatory timelines.
• **Addressing Acute Cannabinoid Overdose (ACO):** The company is developing a treatment for acute cannabinoid overdose, a condition gaining recognition with the evolving landscape of cannabis legalization and increased potency of products. Currently, there are no approved pharmacological treatments specifically for ACO, creating a substantial unmet medical need. This represents a first-in-class opportunity for Opiant to establish market leadership in an emerging therapeutic area. The market for ACO treatment, while nascent, is expected to grow as cannabis use becomes more widespread, positioning Opiant for significant long-term growth if successful, potentially within a 5-7 year timeframe.
• **Advancements in Opioid Use Disorder (OUD) Management:** Beyond acute overdose reversal, Opiant's pipeline includes candidates for opioid use disorders, focusing on long-term management and treatment. OUD remains a pervasive public health challenge, and effective, accessible treatments are crucial for recovery. Developing novel OUD therapies could allow Opiant to capture a share of the multi-billion dollar market for addiction medications, which includes maintenance therapies and relapse prevention. This initiative leverages the company's existing expertise in the opioid space, offering a continuum of care that could enhance patient outcomes and secure a significant market position over the next 4-6 years.
• **Innovations in Opioid Overdose Reversal:** While NARCAN is a key product, Opiant continues to explore new formulations or mechanisms for opioid overdose reversal. The ongoing opioid crisis necessitates continuous innovation to improve efficacy, speed of action, or ease of administration. Any new or improved product in this area could strengthen Opiant's market leadership, potentially addressing limitations of existing treatments or reaching new patient populations. This pursuit ensures the company remains at the forefront of emergency overdose intervention, with potential product enhancements or new offerings emerging within a 2-4 year horizon.
• **Strategic Partnerships and Licensing Opportunities:** As a specialty pharmaceutical company with a focused pipeline, Opiant has the opportunity to engage in strategic partnerships or licensing agreements. Collaborating with larger pharmaceutical companies could provide access to broader distribution networks, additional research and development funding, or expertise in specific therapeutic areas. Such partnerships could accelerate the development and commercialization of its pipeline assets, particularly for global markets, and provide non-dilutive capital. These collaborations could materialize at various stages of product development, offering a flexible growth pathway for the company over the next 1-5 years.

What Opportunities Does OPNT Have?

• Successful development and commercialization of pipeline candidates for alcohol use disorders, acute cannabinoid overdose, and opioid use disorders.
• Expansion of NARCAN's market penetration or development of next-generation overdose reversal products.
• Strategic partnerships or licensing agreements to accelerate development and market access for pipeline assets.
• Growing global demand for addiction treatment solutions due to increasing prevalence of substance use disorders.

What Threats Does OPNT Face?

• Intense competition from larger pharmaceutical companies with greater resources in the addiction treatment space.
• Regulatory hurdles and potential delays or failures in obtaining FDA/EMA approvals for pipeline products.
• Patent expirations or generic competition for existing products, including NARCAN.
• Changes in healthcare policy or reimbursement landscapes affecting access and pricing of addiction treatments.

What Are OPNT's Competitive Advantages?

• **Specialized Focus:** Deep expertise and a dedicated pipeline in addiction and overdose treatments, addressing critical public health needs.
• **Established Product:** Commercial success and brand recognition with NARCAN nasal spray in the opioid overdose reversal market.
• **Regulatory Approvals:** Experience navigating the complex regulatory landscape for pharmaceutical products, particularly with NARCAN.
• **Intellectual Property:** Potential for patent protection and market exclusivity for novel drug candidates emerging from its pipeline.
• **Unmet Needs:** Targeting therapeutic areas with significant unmet medical needs, offering opportunities for first-in-class or best-in-class treatments.

What Does OPNT Do?

Opiant Pharmaceuticals, Inc., incorporated in 2005, commenced its operations as Lightlake Therapeutics Inc. before rebranding to its current name in January 2016. Headquartered in Santa Monica, California, the company operates as a specialty pharmaceutical entity dedicated to addressing the critical public health challenges posed by addictions and drug overdose. Its foundational product, NARCAN nasal spray, is a widely recognized and utilized treatment designed to rapidly reverse the effects of opioid overdoses. This product underscores Opiant's commitment to providing immediate intervention solutions in emergency medical situations. Beyond its commercialized offering, Opiant Pharmaceuticals maintains a robust and focused pipeline of product candidates. These candidates are strategically aimed at developing novel therapeutic solutions for a range of substance use disorders, including further advancements in opioid overdose reversal, treatments for alcohol use disorders, interventions for acute cannabinoid overdose, and long-term management strategies for opioid use disorders. The company's business model centers on the research, development, and commercialization of these specialized pharmaceutical products, leveraging its expertise in addiction medicine to address significant unmet medical needs. With a team of 37 employees, Opiant positions itself within the biotechnology sector by focusing on innovative drug development, from preclinical stages through clinical trials and eventual market introduction, to combat the complex challenges associated with addiction.

What Products and Services Does OPNT Offer?

• Develops medicines for addictions and drug overdose.
• Offers NARCAN nasal spray, a treatment to reverse opioid overdoses.
• Conducts research and development for new product candidates.
• Focuses on treatments for alcohol use disorders.
• Investigates therapies for acute cannabinoid overdose.
• Develops medications for opioid use disorders.
• Operates as a specialty pharmaceutical company.
• Aims to address significant unmet medical needs in public health.

How Does OPNT Make Money?

• Generates revenue from the sales and distribution of NARCAN nasal spray.
• Invests in research and development to advance its pipeline of drug candidates.
• Seeks regulatory approvals for new pharmaceutical products.
• Potentially earns revenue through licensing agreements or partnerships for its pipeline assets.
• Focuses on commercializing specialized treatments for addiction and overdose.

What Industry Does OPNT Operate In?

Opiant Pharmaceuticals operates within the highly specialized and regulated biotechnology industry, specifically targeting the addiction and drug overdose treatment market. This sector is characterized by significant unmet medical needs and a growing public health crisis, particularly concerning opioid and substance use disorders. The global market for addiction treatment is substantial, driven by increasing prevalence rates and a greater emphasis on public health interventions. Opiant's positioning with NARCAN nasal spray provides it with an established commercial presence in the opioid overdose reversal segment. The competitive landscape includes both established pharmaceutical companies and other biotechnology firms developing similar or alternative treatments. Opiant differentiates itself through its focused pipeline addressing specific addiction types, aiming to capture market share through novel therapeutic approaches and improved patient outcomes within this critical healthcare niche.

Who Are OPNT's Key Customers?

• Healthcare providers, including hospitals, clinics, and emergency medical services.
• Patients suffering from opioid overdose, alcohol use disorders, acute cannabinoid overdose, and opioid use disorders.
• Public health organizations and government agencies involved in addiction prevention and treatment.
• Pharmacies and distributors that stock and dispense NARCAN nasal spray.
• Caregivers and individuals trained to administer overdose reversal medications.

How Opiant Pharmaceuticals, Inc. Is Valued

Opiant Pharmaceuticals, Inc. carries a market capitalization of $108.80M, placing it in the micro-cap category. Relative to its peer group, OPNT's quantitative score of 60/100 is below the peer average of 76/100.

Company Profile

Opiant Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Santa Monica, US. The company is led by CEO Roger Crystal. OPNT has traded publicly since 2007.

ROE 7%Key Financial Metrics

Return on equity for Opiant Pharmaceuticals, Inc. stands at 7.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.3%, showing how much profit it generates from its asset base. OPNT trades at a trailing price-to-earnings ratio of 30.58, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.10 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.3%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Opiant Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.86 places it in the grey zone, a middle ground that warrants monitoring.

Net sellingInsider Activity

The most recent 12 insider filings for Opiant Pharmaceuticals, Inc. break down as 12 sales and 0 purchases. On net that is roughly 102K shares disposed (about $1.9M), a signal worth weighing alongside the fundamentals.

OPNT Financials

OPNT Latest News

OPNT Analyst Consensus

OPNT MoonshotScore

Opiant Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources